Simple blood test could transform cancer monitoring

NCT ID NCT06367751

Ongoing Diagnosis Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether liquid biopsies—simple blood tests that detect tumor DNA—can be used during regular doctor visits for people with advanced solid tumors. Researchers will collect blood samples from 159 patients and measure ctDNA levels to see how often the test finds tumor DNA and whether it reveals treatable genetic changes. They will compare results to patients who did not receive the test to understand its real-world usefulness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ctDNA measurement (liquid biopsy blood test)
What this could lead to: If successful, this could show that liquid biopsies are a practical tool for monitoring advanced cancer and identifying treatable genetic changes without invasive tissue biopsies.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly improve outcomes. The test may not detect all tumors, and results may not always change patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Department of Medical Oncology, University Hospital Basel

Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.